Preclinical Development of Tumor-Targeted New Anticancer (Metal) Compounds

Aim of our research is to determine the anticancer properties of novel (metal) compounds and to clarify in how far drug-resistance mechanisms may limit their use in clinical oncology. Moreover, we are interested in a detailed analysis of the activity profile and the underlying cellular and molecular mechanisms with respect to the impact of modifications in the chemical structures. The substance panel includes besides clinically investigated drugs (NKP-46 and NKP-1339) also several compounds in pre-clinical development (e.g. oxaliplatin analogs, thiosemicarbazones, platinum- or lanthanoid-containing compounds, compounds of natural origin). Moreover, several projects aim on the development of chemotherapeutic agents and novel targeted (pro)drugs (e.g. tyrosine kinase inhibitors) specifically targeted to or activated within the malignant tissues. In general, this project has a focus on the translational and integrative cooperation with other scientific disciplines such as analytical and synthetic chemistry, pharmacologists and clinical oncologists.
This focus is part of the interuniversity research platform "Translational Cancer Therapy Research".


Petra Heffeter, Research Assistant
http://krebsforschung.meduniwien.ac.at/researcher/petra_heffeter/
Rita Dornetshuber, Post-Doc 
(in cooperation with Prof. Rosa Lemmens-Gruber, University Vienna)
Christian Kowol, Post-Doc 
(in cooperation with Prof. Bernhard Keppler, University Vienna)
Ute Jungwirth, PhD
Kushtrim Kryeziu, PhD
Walter Miklos, PhD
Diana Groza, Diploma Student

Cooperations:
B. Keppler, V. Arion (Institute of Inorganic Chemistry, Vienna University) 
R. Lemmes-Gruber (Department of Pharmacology and Toxicology, Vienna University)
Prof. Körner (Institute of Geology, Vienna University)
G. Köllensperger (Department of Chemistry, BOKU Vienna)
L. Gille (Molecular Pharmacology and Toxicology Unit, Vet. Med. Vienna)
R. Kiss, V. Mathieu (University Brussels )
A. Casini (University Goningen)
G. Gasser (University Zürich)
I. Ott (University Braunschweig)
Pharmaceutical Companies